Development
Novartis AG
NVS
$117.76
$0.91990.79%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 14.85B | 7.84B | 7.65B | 7.03B | 6.96B |
| Total Depreciation and Amortization | 5.14B | 5.27B | 5.21B | 5.14B | 4.99B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3.62B | 3.31B | 4.21B | 4.99B | 3.86B |
| Change in Net Operating Assets | -1.90B | -1.03B | -1.70B | -1.61B | -1.57B |
| Cash from Operations | 14.46B | 15.37B | 15.37B | 15.54B | 14.24B |
| Capital Expenditure | -1.06B | -960.00M | -920.00M | -896.00M | -916.00M |
| Sale of Property, Plant, and Equipment | 237.00M | 175.00M | 144.00M | 157.00M | 158.00M |
| Cash Acquisitions | -3.56B | -3.56B | -112.00M | -35.00M | -832.00M |
| Divestitures | 3.00M | 0.00 | 6.00M | -23.00M | -8.00M |
| Other Investing Activities | 9.98B | 10.23B | 14.18B | 3.52B | 3.07B |
| Cash from Investing | 5.60B | 5.89B | 13.30B | 2.72B | 1.47B |
| Total Debt Issued | 1.57B | -172.00M | -172.00M | 795.00M | 252.00M |
| Total Debt Repaid | -2.48B | -2.61B | -1.97B | -2.84B | -2.84B |
| Issuance of Common Stock | 158.00M | 158.00M | 158.00M | 165.00M | 100.00M |
| Repurchase of Common Stock | -8.72B | -10.15B | -11.24B | -11.00B | -10.65B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -7.26B | -7.26B | -7.26B | -7.26B | -7.51B |
| Other Financing Activities | 3.48B | 3.38B | -71.00M | -110.00M | 81.00M |
| Cash from Financing | -14.28B | -17.67B | -21.57B | -20.24B | -20.56B |
| Foreign Exchange rate Adjustments | 100.00M | 81.00M | 167.00M | 116.00M | -32.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5.88B | 3.68B | 7.26B | -1.85B | -4.89B |